Grants and Contributions:

Back to search

Title:

Optimization of Dispersin B production in Escherichia coli.

Agreement Number:

EGP

Agreement Value:

$25,000.00

Agreement Date:

Jul 12, 2017 -

Organization:

Natural Sciences and Engineering Research Council of Canada

Location:

Manitoba, CA

Reference Number:

GC-2017-Q2-00048

Agreement Type:

Grant

Report Type:

Grants and Contributions

Additional Information:

Grant or Award spanning more than one fiscal year (2017-2018 to 2018-2019).

Recipient's Legal Name:

Levin, David (University of Manitoba)

Program:

Engage Grants for Universities

Program Purpose:

Kane Biotech Inc. is a Manitoba-based company that provides innovative technologies that break down andx000D
disperse microbial biofilms. Its mission is to discover and commercialize new technologies that will preventx000D
biofilm-related infections in human and animal healthcare, as well as biofilm-related industrial applications.x000D
Dispersin B has been shown to both inhibit and disperse bacterial biofilms. Kane Biotech Inc. has expressedx000D
this enzyme protein in E. coli, with the goal of developing Dispersin B-based products. Dispersin B yield andx000D
the cost effective commercial production of the enzyme are critical factors affecting the market opportunitiesx000D
for Kane Biotech's Dispersin B products, estimated to be $10 million in the next few years. Kane Biotech willx000D
partner with Dr. David Levin, in the Department of Biosystems Engineering at the University of Manitoba, in ax000D
joint research project to optimize production of Dispersin B. The specific goals of the proposed research are tox000D
identify an animal-product-free (APF) cell culture medium that supports maximal cell mass production andx000D
Dispersin B yields, and develop a scale-up fermentation process using the best APF medium in a bioreactorx000D
system.